ﺑﺎﺯﮔﺸﺖ ﺑﻪ ﺻﻔﺤﻪ ﻗﺒﻠﯽ
خرید پکیج
تعداد آیتم قابل مشاهده باقیمانده : 3 مورد
نسخه الکترونیک
medimedia.ir

Oxiconazole: Drug information

Oxiconazole: Drug information
(For additional information see "Oxiconazole: Patient drug information")

For abbreviations, symbols, and age group definitions used in Lexicomp (show table)
Brand Names: US
  • Oxistat
Pharmacologic Category
  • Antifungal Agent, Imidazole Derivative;
  • Antifungal Agent, Topical
Dosing: Adult
Tinea infections

Tinea infections:

Tinea corporis/tinea cruris: Topical: Cream 1%, lotion 1%: Apply to affected and surrounding area(s) 1 to 2 times daily until clinical resolution, typically 1 to 3 weeks (Ref).

Tinea pedis (labeled use)/tinea manuum (off-label use): Topical: Cream 1%, lotion 1%: Apply to affected and surrounding area(s) 1 to 2 times daily until 1 week after clinical resolution, typically for 4 weeks total (Ref).

Tinea versicolor (pityriasis versicolor): Topical: Cream 1%: Apply to affected area(s) and immediate surrounding skin once daily for 2 weeks.

Dosing: Kidney Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.

Dosing: Hepatic Impairment: Adult

There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.

Dosing: Older Adult

Refer to adult dosing.

Dosing: Pediatric
Tinea corporis, tinea cruris, tinea pedis, tinea versicolor

Tinea corporis, tinea cruris, tinea pedis, tinea versicolor (pityriasis versicolor): Children ≥12 years and Adolescents: Topical: Cream: Refer to adult dosing.

Dosing: Kidney Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.

Dosing: Hepatic Impairment: Pediatric

There are no dosage adjustments provided in the manufacturer's labeling; however, dosage adjustment unlikely due to low systemic absorption.

Adverse Reactions

The following adverse drug reactions and incidences are derived from product labeling unless otherwise specified.

1% to 10%:

Central nervous system: Localized burning (≤1%)

Dermatologic: Pruritus (<2%)

<1%, postmarketing, and/or case reports: Allergic contact dermatitis, dyshidrotic eczema, erythema, exfoliation of skin, folliculitis, maceration of the skin, nodule, pain, papule, skin fissure, skin irritation, skin rash, stinging of the skin, tingling of skin

Contraindications

Hypersensitivity to oxiconazole or any component of the formulation

Warnings/Precautions

Concerns related to adverse effects:

• Irritation: Discontinue if sensitivity or irritation occurs

Other warnings/precautions:

• Appropriate use: For topical use only; not for ophthalmologic, oral, or vaginal use.

Dosage Forms: US

Excipient information presented when available (limited, particularly for generics); consult specific product labeling. [DSC] = Discontinued product

Cream, External:

Oxistat: 1% (30 g [DSC], 60 g, 90 g) [contains benzoic acid, cetyl alcohol, propylene glycol]

Generic: 1% (30 g, 60 g, 90 g)

Lotion, External:

Oxistat: 1% (30 mL, 60 mL) [contains benzoic acid, cetyl alcohol, propylene glycol]

Generic Equivalent Available: US

May be product dependent

Pricing: US

Cream (Oxiconazole Nitrate External)

1% (per gram): $10.40

Cream (Oxistat External)

1% (per gram): $13.05

Lotion (Oxistat External)

1% (per mL): $28.05

Disclaimer: A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer. Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions. In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data. Pricing data is updated monthly.

Administration: Adult

For external use only; avoid contact with eyes, nose, mouth, or other mucous membranes. Avoid occlusive dressings unless otherwise directed. Wash hands before and after use.

Administration: Pediatric

Topical: For external use only; avoid contact with eyes, nose, mouth, or other mucous membranes. Apply to the affected area(s) and the immediate surrounding tissue. Avoid occlusive dressings unless otherwise directed. Wash hands before and after use.

Use: Labeled Indications

Tinea infections:

Cream: Topical treatment of tinea pedis (athlete's foot); tinea cruris (jock itch); tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum; and tinea versicolor (pityriasis versicolor) due to Malassezia furfur

Lotion: Treatment of tinea pedis (athlete's foot); tinea cruris (jock itch); tinea corporis (ringworm) due to Trichophyton rubrum, Trichophyton mentagrophytes, or Epidermophyton floccosum

Use: Off-Label: Adult

Tinea manuum

Metabolism/Transport Effects

None known.

Drug Interactions

There are no known significant interactions.

Pregnancy Considerations

When administered orally, teratogenic effects were not observed in animal reproduction studies.

Breastfeeding Considerations

Systemic absorption is low, however, the manufacturer reports that oxiconazole is excreted in breast milk.

Mechanism of Action

The cytoplasmic membrane integrity of fungi is destroyed by oxiconazole which exerts a fungicidal activity through inhibition of ergosterol synthesis. Effective for treatment of tinea pedis, tinea cruris, tinea corporis, and tinea versicolor (pityriasis versicolor). Active against Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton violaceum, Microsporum canis, Microsporum audouinii, Microsporum gypseum, Epidermophyton floccosum, Candida albicans, and Malassezia furfur.

Pharmacokinetics (Adult Data Unless Noted)

Absorption: In each layer of the dermis; very little systemically after one topical dose

Distribution: To each layer of the dermis

Excretion: Urine (<0.3%)

Brand Names: International
International Brand Names by Country
For country code abbreviations (show table)

  • (AT) Austria: Liderman;
  • (BD) Bangladesh: Oxifun | Oxizol;
  • (BR) Brazil: Micotin | Nitrato de oxiconazol | Oceral | Oxipelle;
  • (CO) Colombia: Oxistat;
  • (CZ) Czech Republic: Myfungar;
  • (DE) Germany: Myfungar;
  • (DO) Dominican Republic: Oxistat;
  • (EG) Egypt: Apexazole | Tinox;
  • (ES) Spain: Salongo;
  • (ET) Ethiopia: Oxezole;
  • (FR) France: Fonx;
  • (ID) Indonesia: Oceral;
  • (IN) India: Auxerg | Auxicreme | Oxfaze | Oxicanol | Oxicojen | Oxinext | Pilzban | Zoderm | Zoderm E;
  • (JP) Japan: Benhur ex | Derimine | Okinazole | Saibic | Scorba s;
  • (KR) Korea, Republic of: Oceral | Sylos;
  • (LT) Lithuania: Myfungar;
  • (LV) Latvia: Mifungar | Myfungar;
  • (MA) Morocco: Oxistat;
  • (MX) Mexico: Myfungar | Oxistat;
  • (QA) Qatar: Oxezole | Oxezole Spray;
  • (RU) Russian Federation: Myfungar;
  • (SK) Slovakia: Myfungar;
  • (TH) Thailand: Oceral;
  • (TR) Turkey: Oceral | Oxezole | Zolexol;
  • (TW) Taiwan: Oxistat;
  • (UA) Ukraine: Mifungar;
  • (UY) Uruguay: Oceral;
  • (VE) Venezuela, Bolivarian Republic of: Oxistat
  1. Goldstein AO, Goldstein BG. Dermatophyte (tinea) infections. Post TW, ed. UpToDate. Waltham, MA: UpToDate Inc. http://www.uptodate.com. Accessed August 24, 2021.
  2. Gupta AK, Cooper EA. Update in antifungal therapy of dermatophytosis. Mycopathologia. 2008;166(5-6):353-367. doi:10.1007/s11046-008-9109-0 [PubMed 18478357]
  3. Oxistat (oxiconazole nitrate) lotion [prescribing information]. Baudette, MN: ANI Pharmaceuticals Inc; May 2022.
  4. Oxistat (oxiconazole nitrate) cream [prescribing information]. Melville, NY: PharmaDerm; January 2012.
  5. Refer to manufacturer's labeling.
  6. van Zuuren EJ, Fedorowicz Z, El-Gohary M. Evidence-based topical treatments for tinea cruris and tinea corporis: a summary of a Cochrane systematic review. Br J Dermatol. 2015;172(3):616-641. doi:10.1111/bjd.13441 [PubMed 25294700]
  7. Weinstein A, Berman B. Topical treatment of common superficial tinea infections. Am Fam Physician. 2002;65(10):2095-2102. [PubMed 12046779]
Topic 9727 Version 171.0

آیا می خواهید مدیلیب را به صفحه اصلی خود اضافه کنید؟